Want to see VTVT full AI Analyst Report?
VTVT Stock Chart & Stats
$38.12
$0.06(0.41%)
At close: 4:00 PM EST
$38.12
$0.06(0.41%)
Day’s Range― - ―
52-Week Range$14.00 - $44.00
Previous CloseN/A
Volume611.00
Average Volume (3M)5.07K
Market Cap
$124.74M
Enterprise Value$482.32
Total Cash (Recent Filing)$98.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)1583.0
Beta0.56
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding3,938,654
10 Day Avg. Volume5,801
30 Day Avg. Volume5,072
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)5.23
Price to Sales (P/S)0.00
P/FCF Ratio-13.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$58.17Price Target Upside52.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.4
Revenue Forecast (FY)$28.24M
Bulls Say, Bears Say
Bulls Say
Low Leverage & Improved CapitalizationVery low debt and a materially improved equity base reduce financial fragility and extend runway flexibility. A cleaner capital structure lowers bankruptcy risk and gives management optionality to fund R&D, partner deals, or withstand trial delays without urgent refinancing.
Late-Stage Pipeline CatalystA moving Phase 3 program provides a clear, durable value inflection: successful readout can unlock partnerships, milestones, and commercialization paths. This late-stage asset materially changes upside potential and supports strategic options over the next 2–6+ months.
Enhanced Financing FlexibilityBroadening the ATM capacity institutionalizes a flexible, ongoing capital source. That structural tool lets management raise incremental funds quickly and with lower transaction friction to support multi-stage trials, reducing the need for single large dilutive financings.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flows signal reliance on external capital to fund operations. Sustained burn increases execution risk if markets access tightens, forcing dilutive raises or spending cuts that can slow development timelines and damage program continuity.
Structural UnprofitabilityOngoing operating losses and volatile/absent revenue indicate core earnings power is not yet established. Until commercialization or durable licensing revenue emerges, profitability depends on non‑operating items or one-time events, increasing long-term execution and funding uncertainty.
Reliance On Equity Markets (Dilution Risk)Expanding the ATM program underlines dependence on equity markets to fund growth. While flexible, routine share issuance risks dilution, can compress per-share economics over time, and makes long-term planning contingent on market receptivity rather than operational cash generation.
vTv Therapeutics News
VTVT FAQ
What was vTv Therapeutics’s price range in the past 12 months?
vTv Therapeutics lowest stock price was $14.00 and its highest was $44.00 in the past 12 months.
What is vTv Therapeutics’s market cap?
vTv Therapeutics’s market cap is $124.74M.
When is vTv Therapeutics’s upcoming earnings report date?
vTv Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 104 days.
How were vTv Therapeutics’s earnings last quarter?
vTv Therapeutics released its earnings results on May 13, 2026. The company reported $1.65 earnings per share for the quarter, beating the consensus estimate of $0.21 by $1.44.
Is vTv Therapeutics overvalued?
According to Wall Street analysts vTv Therapeutics’s price is currently Undervalued.
Does vTv Therapeutics pay dividends?
vTv Therapeutics does not currently pay dividends.
What is vTv Therapeutics’s EPS estimate?
vTv Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does vTv Therapeutics have?
vTv Therapeutics has 3,938,654 shares outstanding.
What happened to vTv Therapeutics’s price movement after its last earnings report?
vTv Therapeutics reported an EPS of $1.65 in its last earnings report, beating expectations of $0.21. Following the earnings report the stock price went up 21.364%.
Which hedge fund is a major shareholder of vTv Therapeutics?
Currently, no hedge funds are holding shares in VTVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
vTv Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.17 (52.59% Upside)
$58.17 (52.59% Upside)
Blogger Sentiment
Bullish
VTVT Sentiment 100%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
208.53%
Trailing 12-Months
Company Description
vTv Therapeutics
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
VTVT Stock 12 Month Forecast
Average Price Target
$58.17
▲(52.59% Upside)
Technical Analysis
Ownership Overview
11.52% Insiders
10.03% Mutual Funds
<0.01% Other Institutional Investors
75.83% Public Companies and
Individual Investors